Regencell Bioscience Holdings Limited income statement RGC
It recorded a net loss of $11.7 million. Diluted earnings per share were -$2.37.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.
| Line |
FY 2026
Jun 30, 2026
|
FY 2025
Jun 30, 2025
|
FY 2024
Jun 30, 2024
|
FY 2023
Jun 30, 2023
|
FY 2021
Jun 30, 2021
|
|---|---|---|---|---|---|
| Research and development |
1
+37.0%
|
1
-11.1%
|
1
-32.6%
|
2
-37.0%
|
0
|
| Selling, general and administrative |
10
+269.5%
|
3
-23.1%
|
4
-21.8%
|
5
-8.1%
|
1
|
| Operating income |
-12
-211.0%
|
-4
+20.4%
|
-5
+24.5%
|
-6
+17.6%
|
-1
|
| Interest income |
0
-87.9%
|
0
-25.1%
|
0
+190.4%
|
0
|
—
|
| Pretax income |
-12
-226.5%
|
-4
+17.9%
|
-4
+28.0%
|
-6
+20.2%
|
-1
|
| Net income |
-12
-226.5%
|
-4
+16.7%
|
-4
+26.7%
|
-6
|
-1
|
| Basic EPS |
-2.37
-229.2%
|
-0.72
+17.2%
|
-0.87
+26.9%
|
-1.19
-105.2%
|
—
|
| Diluted EPS |
-2.37
-229.2%
|
-0.72
+17.2%
|
-0.87
+26.9%
|
-1.19
-105.2%
|
—
|
| Weighted average shares, basic |
495
+0.0%
|
494
+0.0%
|
494
+0.0%
|
494
+3761.5%
|
10
|
| Weighted average shares, diluted |
495
+0.0%
|
494
+0.0%
|
494
+0.0%
|
494
+3761.5%
|
—
|
| Other measures | |||||
| Depreciation and amortization |
0
+4.1%
|
0
-74.6%
|
0
+4.3%
|
0
+95.2%
|
0
|
| EBITDA |
-12
-215.3%
|
-4
+16.7%
|
-4
+25.9%
|
-6
+19.9%
|
-1
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- RGC (Nasdaq)
- Incorporated in
- Cayman Islands
- Headquarters
- Hong Kong
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1829667
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
- Aurora Cannabis Inc ACB
Source: SEC EDGAR filings. This is company-reported data, not investment advice.